Navigation Links
ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development

SHANGHAI, Sept. 15, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner ("ChemPartner"), a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies ("mAbs").

Through the partnership, ChemPartner and Hengrui will initially collaborate on the development of novel therapeutic mAbs in a major therapeutic area. ChemPartner will head pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and preformulation studies, while Hengrui will lead drug development for the mAb. Following the project's completion, Hengrui will retain the intellectual property rights of the mAb and any patents related to the mAb's development. The first program will have several preclinical and development milestone payments, as well as a timeline-based incentive payment.

Mr. Michael Xin Hui, chairman and chief executive officer of ShangPharma, commented, "Hengrui is the first major domestic pharmaceutical company to form such an antibody partnership with ChemPartner, and the program is the first of its kind in China. The indication and market potential for the first mAb is very broad. We are proud to be working with Hengrui, one of the major domestic pharmaceutical companies. We expect our collaborative work will lead to further domestic and multinational partnerships in biologics development, and pave the way for innovation and growth in China's own biotechnology industry."

Dr. Lianshan Zhang, Hengrui's President of Global R&D, added, "Hengrui, as a domestic leader in innovative medicines, recognizes the importance of external discovery capability, especially in the area of biotherapeutics. We are pleased to be working with one of the leading CRO companies in China. Hengrui has chosen to partner with ShangPharma and its ChemPartner subsidiary for their exceptional capabilities and platform in biologics R&D, and we will work together toward a successful partnership."

About JiangsuHengrui Medicine Co., Ltd.Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with net sales of about US$550 million in 2010. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with over a dozen of new molecular entities in clinical trials and dozens more under pre-clinical development. Hengrui's products and R&D span over multiple therapeutic areas, such as oncology, cardiovascular and metabolic diseases, CNS, inflammation, hematology and anesthesiology. For more information, please visit

About Shanghai ChemPartnerFounded in 2003, Shanghai ChemPartner (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including more than 100 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies. Headquartered in China, ChemPartner has overseas business development operations in Boston, USA and Copenhagen, Denmark. For more information, please visit

About ShangPharma Corporation  ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit For further information, please contact:ShangPharma CorporationIn Shanghai, ChinaMs. Lan XieVP of Finance and Investor RelationsEmail: ChristensenIn New York:Kimberly MinarovichTel: +1 917-533-3268Email: In Hong Kong:Tip Fleming Tel: +852-9212-0684Email:

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ShangPharma Announces Second Quarter 2011 Results
2. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
3. ShangPharma Announces First Quarter 2011 Results
4. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
5. ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
6. Infrared Systems Internationals Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Laymans Terms
7. Infrared Systems Internationals Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS
8. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
9. New England Biolabs Opens New Subsidiary Office in France
10. Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc.
11. China Cord Blood Corporation Forms Zhejiang Subsidiary
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):